FASN and breast cancer: PI3K activity was thought to be the mediator of the HER2 control on FASN expression because LY294002, a known PI3K inhibitor, abrogated HER2 induced FASN protein production in the HER2 overexpressing normal mammary epithelial and breast cancer cells.